ErlySign appoints Akshay Churi as Vice President of manufacturing to accelerate early cancer detection solutions

New Delhi: ErlySign, the Nagpur-based biotech startup developing India’s first salivary biomarker–based screening test for early-stage cancer detection, has announced the appointment of Akshay Churi as Vice President, Manufacturing.

The appointment comes as the company strengthens its leadership team to support the commercialisation and scale-up of its saliva-based early oral cancer detection technologies.

Akshay brings over two decades of experience in medical technology, biosciences, and precision manufacturing, having previously served as Business Manager at Husky Technologies for South-East Asia and Middle East, at ZAHORANSKY, and previously has over 13 years of experience building and scaling precision manufacturing programs, with strong expertise in mould development, project management, and strategic customer partnerships in the automotive sector.

At ErlySign, he will leverage this extensive experience to establish and scale the company’s manufacturing operations, including setting up a cleanroom facility, building and leading a high-performance team, securing regulatory approvals, and ensuring strong quality, compliance, and operational excellence standards while aligning plant performance and productivity with the company’s commercial growth objectives.

Commenting on the appointment, Shubhendra, Founder and CEO of ErlySign, said, “Akshay’s appointment aligns with our vision to expand access to affordable and scalable early cancer detection solutions. With his strong expertise in medical manufacturing and operational execution, we are confident he will strengthen our manufacturing readiness, enhance our go to market strategy, and help build key industry partnerships as we move toward commercialisation and global growth.”

Speaking about his new role, Akshay Churi said, “I am excited to join ErlySign at such a transformative stage. The company’s mission to make early cancer detection accessible and non-invasive has the potential to impact millions of lives. I look forward to building strong partnerships, scaling our solutions, and contributing to a healthcare ecosystem focused on prevention and early diagnosis.”